Search results for "GLUTAMATE"

showing 10 items of 434 documents

Unit study in cat claustrum of the effects of iontophoretic neurotransmitters and correlations with the effects of activation of some afferent pathwa…

1982

Glutamate (Glut), acetylcholine (ACh) and dopamine (DA) were iontophoretically applied on cat claustral neurons. Glut did not affect all the neurons; ACh had both excitatory and inhibitory effects, while DA was prevalently inhibitory. An analysis was made of the time-course of excitatory and inhibitory responses on the basis of the mean firing rate variations during and after ACh and DA release. Three types of responses are described for each drug: short lasting inhibition, long lasting inhibition and long lasting excitation. The experimental data were statistically elaborated. The effects of ACh and of DA were compared with those of activation obtained by sensorial peripheric and thalamic …

Afferent PathwaysNeurotransmitter AgentsIontophoresisPhysiologyChemistryDopamineGlutamate receptorIontophoresisInhibitory postsynaptic potentialBiochemistryClaustrumAcetylcholineBasal GangliaAcoustic StimulationDopamineAfferentCatsmedicineExcitatory postsynaptic potentialAnimalsNeuroscienceAcetylcholinemedicine.drugArchives Internationales de Physiologie et de Biochimie
researchProduct

Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer’s and Prion diseases

1998

Alzheimer's disease, a major form of dementia in the elderly has become an increasingly important health problem in developed countries. In vitro studies on primary neurons demonstrate that Flupirtine (Katadolon) at a concentration of 1 microg/ml, significantly reduces the neurotoxic (apoptotic) effect displayed by A beta25-35, a segment of the amyloid beta-protein precursor the etiologic agent of Alzheimer's disease. Flupirtine, which has been in clinical use since 10 years ago, prevents the toxic effect of PrP, the presumed etiologic agent of the Creutzfeldt-Jakob disease as well as the excitatory amino acid glutamate on cortical neurons. Flupirtine displays a bimodal activity. Its strong…

AgingTime FactorsCell SurvivalPrionsMolecular Sequence DataAminopyridinesApoptosisPharmacologyBiologyNeuroprotectionPrion Diseaseschemistry.chemical_compoundGlutamatesAlzheimer DiseasemedicineAnimalsAmino Acid SequenceRats WistarCells CulturedNeuronsAmyloid beta-PeptidesGlutamate receptorNeurotoxicityBiological activityGlutathionemedicine.diseasePeptide FragmentsRatsNeuroprotective Agentsmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2BiochemistrychemistryCalciumNeuronAlzheimer's diseaseFlupirtineDevelopmental Biologymedicine.drugMechanisms of Ageing and Development
researchProduct

Glutamate Activates Phospholipase D in Hippocampal Slices of Newborn and Adult Rats

1993

Phospholipase D (PLD) is activated by many neurotransmitters in a novel signal transduction pathway. In the present work, PLD activity was studied comparatively in hippocampal slices of newborn and adult rats. Basal PLD activity in adult rats was almost three times higher than in newborn rats. In newborn rats, L-glutamate and 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) time- and concentration-dependently enhanced the formation of [3H]phosphatidylpropanol ([3H]PP) and of [3H]phosphatidic acid in the presence of 2% propanol. N-Methyl-D-aspartate and kainate (both 1 mM) caused small, but significant increases (approximately 50%), whereas alpha-amino-3-hydroxy-5-methylisoxazole…

Agingmedicine.medical_specialtyGlutamic AcidKainate receptorIn Vitro TechniquesBiologyHippocampal formationKynurenateHippocampusBiochemistryCellular and Molecular Neurosciencechemistry.chemical_compoundGlutamatesInternal medicinePhospholipase DmedicineAnimalsCycloleucineNeurotransmitterPhospholipase DGlutamate receptorPhosphatidic acidRatsEnzyme ActivationMetabotropic receptorEndocrinologyAnimals NewbornchemistryBiochemistryJournal of Neurochemistry
researchProduct

Impaired calcium homeostasis in aged hippocampal neurons

2009

Abstract Development of neurodegenerative diseases such as Alzheimer's and Parkinson's disease is strongly age-associated. The impairment of calcium homeostasis is considered to be a key pathological event leading to neuronal dysfunction and cell death. However, the exact impact of aging on calcium homeostasis in neurons remains largely unknown. In the present work we have investigated intracellular calcium levels in cultured primary hippocampal neurons from young (2 months) and aged (24 months) rat brains. Upon stimulation with glutamate or hydrogen peroxide aged neurons in comparison to young neurons demonstrated an increased vulnerability to these disease-related toxins. Measurement of c…

Agingmedicine.medical_specialtyNeurotoxinsGlutamic Acidchemistry.chemical_elementHippocampusBiologyCalciumHippocampusCalcium in biologyRats Sprague-DawleyInternal medicinemedicineAnimalsCalcium SignalingOrganic ChemicalsCells CulturedCellular SenescenceNeuronsCalcium metabolismCalpainGeneral NeuroscienceNeurodegenerationGlutamate receptorCalpainHydrogen PeroxideOxidantsmedicine.diseaseRatsOxidative Stressmedicine.anatomical_structureEndocrinologynervous systemchemistryNerve Degenerationbiology.proteinCalciumNeuronNeuroscienceNeuroscience Letters
researchProduct

ADAM-10 over-expression increases cortical synaptogenesis.

2006

Cortical cholinergic, glutamatergic and GABAergic terminals become upregulated during early stages of the transgenic amyloid pathology. Abundant evidence suggests that sAPP alpha, the product of the non-amyloidogenic alpha-secretase pathway, is neurotrophic both in vitro and when exogenously applied in vivo. The disintegrin metalloprotease ADAM-10 has been shown to have alpha-secretase activity in vivo. To determine whether sAPP alpha has an endogenous biological influence on cortical presynaptic boutons in vivo, we quantified cortical cholinergic, glutamatergic and GABAergic presynaptic bouton densities in either ADAM-10 moderate expressing (ADAM-10 mo) transgenic mice, which moderately ov…

Agingmedicine.medical_specialtySynaptogenesisPresynaptic TerminalsAlpha (ethology)Mice TransgenicBiologyReceptors Metabotropic GlutamateGlutamatergicADAM10 ProteinMiceReceptors GABAInternal medicinemedicineAnimalsHumansReceptors CholinergicCerebral CortexGeneral NeuroscienceGene Expression Regulation DevelopmentalMembrane Proteinscarbohydrates (lipids)ADAM Proteinsmedicine.anatomical_structureEndocrinologyCerebral cortexSynaptic plasticitySynapsesbiology.proteinGABAergicCholinergicCattleNeurology (clinical)Geriatrics and GerontologyAmyloid Precursor Protein SecretasesDevelopmental BiologyNeurotrophinNeurobiology of aging
researchProduct

Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission

2012

Biphasic effects of cannabinoids have been shown in processes such as feeding behavior, motor activity, motivational processes and anxiety responses. Using two different tests for the characterization of anxiety-related behavior (elevated plus-maze and holeboard), we first identified in wild-type C57BL/6N mice, two doses of the synthetic CB1 cannabinoid receptor agonist CP-55,940 with anxiolytic (1 mug/kg) and anxiogenic properties (50 mug/kg), respectively. To clarify the role of CB1 receptors in this biphasic effect, both doses were applied to two different conditional CB1 receptor knockout (KO) mouse lines, GABA-CB1-KO (CB1 receptor inactivation in forebrain GABAergic neurons) and Glu-CB…

AgonistMaleCannabinoid receptormedicine.drug_classmedicine.medical_treatmentGlutamic AcidCyclopentanesPharmacologyGABAB receptorBiologyAnxietyMotor ActivityAnxiolyticSynaptic TransmissionGlutamatergicMiceReceptor Cannabinoid CB1medicineAnimalsGABA Agonistsgamma-Aminobutyric AcidPharmacologyMice KnockoutBehavior AnimalDose-Response Relationship DrugCannabinoidsfood and beveragesCyclohexanolsMice Inbred C57BLPsychiatry and Mental healthPyrimidinesAnxiogenicnervous systemReceptors GABA-BGABAergiclipids (amino acids peptides and proteins)Original ArticleCannabinoidpsychological phenomena and processes
researchProduct

Exploring kainate receptor pharmacology using molecular dynamics simulations.

2010

Ionotropic glutamate receptors (iGluRs) are enticing targets for pharmaceutical research; however, the search for selective ligands is a laborious experimental process. Here we introduce a purely computational procedure as an approach to evaluate ligand–iGluR pharmacology. The ligands are docked into the closed ligand-binding domain and during the molecular dynamics (MD) simulation the bi-lobed interface either opens (partial agonist/antagonist) or stays closed (agonist) according to the properties of the ligand. The procedure is tested with closely related set of analogs of the marine toxin dysiherbaine bound to GluK1 kainate receptor. The modeling is set against the abundant binding data …

AgonistModels Molecularmedicine.drug_classProtein ConformationIn silicoKainate receptorPharmacologyMolecular Dynamics SimulationLigandsPartial agonistArticleTurn (biochemistry)Cellular and Molecular NeuroscienceStructure-Activity RelationshipReceptors Kainic AcidmedicineStructure–activity relationshipPharmacologyAlanineMolecular StructureChemistryBridged Bicyclo Compounds HeterocyclicIonotropic glutamate receptorMarine ToxinsMarine toxinProtein BindingNeuropharmacology
researchProduct

Structural Mechanism of N-Methyl-D-Aspartate Receptor Type 1 Partial Agonism

2012

N-methyl-D-aspartate (NMDA) receptors belong to a family of ionotropic glutamate receptors that contribute to the signal transmission in the central nervous system. NMDA receptors are heterotetramers that usually consist of two GluN1 and GluN2 monomers. The extracellular ligand-binding domain (LBD) of a monomer is comprised of discontinuous segments that form the functional domains D1 and D2. While the binding of a full agonist glycine to LBD of GluN1 is linked to cleft closure and subsequent ion-channel opening, partial agonists are known to activate the receptor only sub-maximally. Although the crystal structures of the LBD of related GluA2 receptor explain the mechanism for the partial a…

AgonistProtein Structuremedicine.drug_classGlycineMolecular ConformationBiophysicslcsh:MedicineMolecular Dynamics SimulationLigandsta3111Receptors N-Methyl-D-AspartateBiochemistryBiophysics Simulationsta3112Partial agonistIon ChannelsChemical BiologyMacromolecular Structure AnalysismedicineBiomacromolecule-Ligand Interactionslcsh:ScienceReceptorBiologyta116Ion channelCrystallographyMultidisciplinaryChemistrylcsh:Rta1182Glutamate receptorProteinsComputational BiologyNeurotransmittersProtein Structure TertiaryTransmembrane ProteinsBiochemistryCycloserineBiophysicsNMDA receptorLigand-gated ion channellcsh:Qhormones hormone substitutes and hormone antagonistsProtein BindingResearch ArticleNeuroscienceIonotropic effectPLoS ONE
researchProduct

Activation of phospholipases C and D by the novel metabotropic glutamate receptor agonist tADA.

1997

Abstract In hippocampal slices taken from 8-day-old rats, trans-azetidine-2,4-dicarboxylic acid (tADA), a novel glutamatergic agonist acting preferentially at class I mGluR receptors, activates phosphoinositide and phosphatidylcholine hydrolysis with widely different potencies. Inositol phosphate formation was maximally increased at 10 μM tADA ( ec 50: 1.2 μM), while phospholipase D activation was observed at a tADA concentration of 1 mM. This is the first report of a tADA-induced phospholipase D activity. © 1997 Elsevier Science Ltd. All rights reserved.

Agonistmedicine.drug_classInositol PhosphatesPhospholipaseBiologyIn Vitro TechniquesReceptors Metabotropic GlutamateHippocampusRats Sprague-DawleyCellular and Molecular NeurosciencemedicineExcitatory Amino Acid AgonistsPhospholipase DPhospholipase D activityAnimalsInositol phosphatePharmacologychemistry.chemical_classificationPhospholipase CPhospholipase DRatsEnzyme ActivationMetabotropic receptorBiochemistrychemistryMetabotropic glutamate receptorType C PhospholipasesAzetidinecarboxylic AcidNeuropharmacology
researchProduct

Modulatory effects of the novel TrkB receptor agonist 7,8-dihydroxyflavone on synaptic transmission and intrinsic neuronal excitability in mouse visu…

2013

7,8-Dihydroxyflavone (7,8 DHF) is a new recently identified TrkB receptor agonist, which possesses a potent neurotrophic activity and shares many physiological properties with the neurotrophin "Brain Derived Neurotrophic Factor" (BDNF). However, its precise mechanism of action at the cellular level has not been clarified yet. In the present study we explored the effects of this agent on synaptic and intrinsic neuronal properties by performing whole-cell patch clamp recordings from layer 2/3 pyramidal neurons. Incubation of acute cortical slices with 7,8-DHF (20 µM) for 30 min caused a selective reduction in the strength of GABAergic inhibition. The amplitude of evoked inhibitory postsynapti…

Agonistmedicine.drug_classNerve Tissue ProteinsTropomyosin receptor kinase BNeurotransmissionIn Vitro Techniques78-DihydroxyflavoneInhibitory postsynaptic potentialSynaptic TransmissionGlutamatergicMicemedicineElectric ImpedanceAnimalsReceptor trkBGABA-A Receptor AntagonistsGABAergic NeuronsProtein Kinase InhibitorsCells CulturedNootropic AgentsVisual CortexPharmacologyBrain-derived neurotrophic factorbiologyPyramidal CellsNeural InhibitionFlavonesReceptors GABA-AMice Inbred C57BLKineticsNeuroprotective Agentsbiology.proteinEvoked Potentials VisualNeuroscienceNeurotrophinEuropean journal of pharmacology
researchProduct